Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia

被引：2

作者：

Pitt, Bertram ^{[1
]}

Anker, Stefan D. ^{[2
]}

Lund, Lars H. ^{[3
,4
]}

Coats, Andrew J. S. ^{[5
]}

Filippatos, Gerasimos ^{[6
]}

Rossignol, Patrick ^{[7
,8
,9
,10
,11
]}

Weir, Matthew R. ^{[12
]}

Friede, Tim ^{[13
,14
]}

Kosiborod, Mikhail N. ^{[15
,16
]}

Metra, Marco ^{[17
,18
]}

Boehm, Michael ^{[19
]}

Ezekowitz, Justin A. ^{[20
]}

Bayes-Genis, Antoni ^{[21
,22
]}

Mentz, Robert J. ^{[23
]}

Ponikowski, Piotr ^{[24
]}

Senni, Michele ^{[25
]}

Pina, Ileana L. ^{[26
]}

Pinto, Fausto J. ^{[27
]}

van der Meer, Peter ^{[28
]}

Bahit, Cecilia ^{[29
]}

Belohlavek, Jan ^{[30
]}

Brugts, Jasper J. ^{[31
]}

Perrin, Amandine ^{[32
]}

Waechter, Sandra ^{[32
]}

Budden, Jeffrey ^{[33
]}

Butler, Javed ^{[34
]}

机构：

[1] Univ Michigan, Dept Cardiol, 1301 Catherine St, Ann Arbor, MI 48109 USA

[2] Charite, Inst Hlth Ctr Regenerat Therapies BCRT, Dept Cardiol CVK German Heart Ctr Charite, German Ctr Cardiovasc Res DZHK,Partner Site Berli, Berlin, Germany

[3] Karolinska Inst, Dept Med, Unit Cardiol, Solna, Sweden

[4] Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden

[5] Heart Res Inst, Sydney, NSW, Australia

[6] Natl & Kapodistrian Univ Athens, Sch Med, Athens Univ Hosp Attikon, Athens, Greece

[7] Princess Grace Hosp, Med Specialties Dept, Fontvieille, Monaco

[8] Princess Grace Hosp, Dept Nephrol, Fontvieille, Monaco

[9] Monaco Private Hemodialysis Ctr, Fontvieille, Monaco

[10] Univ Lorraine, CHRU, Ctr Invest Clin Plurithemat 14 33, INSERM,U1116, Nancy, France

[11] F CRIN INI CRCT Cardiovasc & Renal Clin Trialists, Nancy, France

[12] Univ Maryland, Sch Med, Dept Med, Div Nephrol, Baltimore, MD USA

[13] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany

[14] German Ctr Cardiovasc Res DZHK, Partner Site Gottingen, Gottingen, Germany

[15] St Lukes Mid Amer Heart Inst, Dept Cardiovasc Dis, Sch Med, Kansas City, MO USA

[16] Univ Missouri Kansas City, Med Specialties Dept, Kansas City, MO USA

[17] ASST Spedali Civili, Cardiol, Brescia, Italy

[18] Univ Brescia, Brescia, Italy

[19] Saarland Univ, Klin Innere Med 3, Homburg, Germany

[20] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada

[21] Hosp Badalona Germans Trias & Pujol, Cardiol Dept, Barcelona, Spain

[22] CIBERCV, Barcelona, Spain

[23] Duke Univ, Sch Med, Dept Med, Durham, NC USA

[24] Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland

[25] Univ Milano Bicocca, Papa Giovanni XXIII Hosp, Cardiovasc Dept, Bergamo, Italy

[26] Cent Michigan Univ, Coll Med, Mt Pleasant, MI USA

[27] Univ Lisbon, Santa Maria Univ Hosp, Fac Med, CAML,CCUL, Lisbon, Portugal

[28] Univ Med Ctr Groningen, Fac Med & Dent, Groningen, Netherlands

[29] INECO Neurociencias Orono, Rosario, Santa Fe, Argentina

[30] Gen Univ Hosp Prague, Clin Cardiol & Angiol, Prague, Czech Republic

[31] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands

[32] CSL Vifor, Glattbrugg, Switzerland

[33] CSL Vifor, Redwood City, CA USA

[34] Univ Mississippi, Dept Med, Jackson, MS USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 84卷 / 14期

关键词：

heart failure; hyperkalemia; patiromer; mineralocorticoid receptor antagonists; renin-angiotensin system inhibitors; REDUCED EJECTION FRACTION; POTASSIUM BINDER; EFFICACY; SAFETY;

D O I：

10.1016/j.jacc.2024.05.079

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). OBJECTIVES This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) run-in phase.<br /> METHODS Patients with HFrEF and HK or past HK entered a run-in phase of <= 12 weeks with patiromer-facilitated RAS inhibitor/MRA optimization to achieve >= 50% recommended RAS inhibitor dose, 50 mg/d MRA, and normokalemia. Patients achieving these criteria (randomized group) were compared with the run-in failure group (patients not meeting the randomization criteria).<br /> RESULTS Of 1,038 patients completing the run-in, 878 (84.6%) were randomized and 160 (15.4%) were run-in failures. Overall, 422 (40.7%) had HK entering run-in with a similar frequency in the randomized and run-in failure groups (40.3% vs 42.5%; P 1 / 4 0.605). From start to the end of run-in, in the randomized group, an increase was observed in target RAS inhibitor and MRA use in patients with HK (RAS inhibitor: 76.8% to 98.6%; MRA: 35.9% to 98.6%) and past HK (RAS inhibitor: 60.5% to 98.1%; MRA: 15.6% to 98.7%). Despite not meeting the randomization criteria, an increase after runin was observed in the run-in failure group in target RAS inhibitor (52.5% to 70.6%) and MRA use (15.0% to 48.1%). This increase was observed in patients with HK (RAS inhibitor: 51.5% to 64.7%; MRA: 19.1% to 39.7%) and past HK (RAS inhibitor: 53.3% to 75.0%; MRA: 12.0% to 54.3%).<br /> CONCLUSIONS In patients with HFrEF and HK or past HK receiving suboptimal RAS inhibitor/MRA therapy, RAS inhibitor/MRA optimization increased during patiromer-facilitated run-in. (JACC. 2024;84:1295-1308)]

引用

页码：1295 / 1308

页数：14

共 50 条

[31] REPLY: The Impact of Patiromer on Heart Failure Treatment With Angiotensin Inhibitors and MRAs
Pitt, Bertram
Budden, Jeffrey
Anker, Stefan D.
Butler, Javed
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (10) : e115 - e115
[32] The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure
Braunwald, Eugene
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : 1029 - 1041
[33] Mineralocorticoid receptor antagonist added to angiotensin-converting enzyme inhibitor ameliorates the transition to diastolic heart failure by decreasing myocardial oxidative stress
Kimata, H
Obata, K
Saka, M
Cheng, XW
Hayashi, K
Ichihara, S
CIRCULATION, 2005, 112 (17) : U512 - U512
[34] The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure
Young, Morag J.
Kanki, Monica
Karthigan, Nikshay
Konstandopoulos, Penny
ENDOCRINOLOGY, 2021, 162 (11)
[35] A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain
Ramon Gonzalez-Juanatey, Jose
Gonzalez-Franco, Alvaro
de Sequera, Patricia
Valls, Marta
Ramirez de Arellano, Antonio
Pomares, Elisenda
Nieves, Diana
JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 640 - 649
[36] Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
Hermann Haller
Anna Bertram
Klaus Stahl
Jan Menne
Current Hypertension Reports, 2016, 18
[37] Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
Haller, Hermann
Bertram, Anna
Stahl, Klaus
Menne, Jan
CURRENT HYPERTENSION REPORTS, 2016, 18 (05)
[38] Variation in Laboratory Monitoring After Initiation of a Mineralocorticoid Receptor Antagonist in Patients With Heart Failure
Chauhan, Vishal R.
Dev, Sandesh
Pham, Michael
Lin, Shoutzu
Heidenreich, Paul
CIRCULATION, 2014, 130
[39] Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
Suzuki, Sho
Motoki, Hirohiko
Kanzaki, Yusuke
Maruyama, Takuya
Hashizume, Naoto
Kozuka, Ayako
Yahikozawa, Kumiko
Kuwahara, Koichiro
ESC HEART FAILURE, 2020, 7 (05): : 2752 - 2761
[40] Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure
Kimura, Masayasu
Ogawa, Hiroshi
Wakeyama, Takatoshi
Takaki, Akira
Iwami, Takahiro
Hadano, Yasuyuki
Mochizuki, Mamoru
Hiratsuka, Atsushi
Shimizu, Akihiko
Matsuzaki, Masunori
JOURNAL OF CARDIOLOGY, 2011, 57 (02) : 208 - 214

← 1 2 3 4 5 →